Table TDI-25 part (iv). Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2003: the combination of cannabis, opiates, cocaine or other stimulants as primary drug type with a secondary drug. All clients with stimulants other than cocaine as primary drug: numbers reporting the stated drug as secondary

Country

Opiates

Cocaine

Other stimulants

Hypnotics, sedatives

Hallucinogens

Volatile inhalants

Cannabis

Alcohol

Others

Total

Czech Republic

95

6

42

17

35

31

293

34

1

554

Denmark

 

 

 

 

 

2

91

82

13

188

Germany

 

 

 

 

 

0

62

22

3

87

Greece

2

3

2

1

2

0

5

0

0

15

Cyprus

 

3

 

 

 

 

 

 

 

3

Latvia

 

2

 

 

 

 

12

26

1

41

Luxembourg

 

 

 

 

 

 

2

1

 

3

Hungary

1

8

 

1

7

3

40

71

7

138

Malta

 

2

 

 

1

 

1

 

 

4

Netherlands

6

80

66

7

4

1

101

72

6

343

Slovenia

 

 

1

 

 

 

4

 

 

5

Slovakia

40

16

50

2

27

2

109

16

1

263

Finland

114

2

 

91

1

 

228

111

3

550

Bulgaria

 

 

 

 

 

 

 

1

 

1

Total

258

122

161

119

77

39

948

436

35

2195

Notes:

Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients

Opiates include: heroin, methadone, other opiates; Cocaine includes: Cocaine CIH, crack cocaine; Stimulants include: amphetamines, MDMA and derivates, other stimulants: Cannabis can include herb or resin. For each client up to four secondary drugs can be reported

A number of the clients report using the same drug both as primary and secondary drug, particulary for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. The greater part of clients using cannabis both as primary and secondary drug comes from Germany

Source:

2004 Reitox national reports – see [Table TDI-19]

Data filter | tditab25d-en.xml